[What factors influence healing of duodenal ulcer when Helicobacter pylori eradication treatment is used?].
OBJECTIVE
To study the influence of various factors on duodenal ulcer healing, specially the success or failure of Helicobacter pylori eradication.


METHODS
One-hundred and nine patients with duodenal ulcer and H. pylori infection were studied. At endoscopy biopsies were obtained from the gastric antrum and body, and processed by microbiological (Gram stain and culture) and histological methods (haematoxylin-eosin); also, a 13C breath test was performed. A <<classical >> triple therapy (bismuth, tetracycline, metronidazole) or omeprazole plus amoxicillin was administered. Endoscopy and breath test were repeated one month after completing therapy. Eradication was defined as the absence of H. pylori by all diagnostic methods.


RESULTS
H. pylori eradication was achieved in 60 patients (55%). In the multivariate analysis H. pylori eradication was the only variable which correlated with ulcer healing (regr. coef. = 2.4; OR = 10.6). Additional variables (age, sex, smoking, time of evolution, ulcer size, and type of therapy) were not significantly correlated. Ulcer healing was achieved in 92% of patients after H. pylori eradication, and in 51% of therapy failures (p < 0.001).


CONCLUSIONS
H. pylori eradication accelerates ulcer healing, which represents an additional argument for employing eradicating therapy in patients with duodenal ulcer disease.
Gisbert
J P
JP
Servicio de Gastroenterología, Hospital Ramón y Cajal, Departamento de Medicina, Universidad de Alcalá de Henares, Madrid.
Boixeda
D
D
de Rafael
L
L
Alvarez Baleriola
I
I
Martín de Argila
C
C
García
M
M
García Plaza
A
A
D000328:Adult; D000367:Age Factors; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage; D000863:Antacids / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D001729:Bismuth / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000503:physiopathology; D005069:Evaluation Studies as Topic; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage; D008875:Middle Aged; D015999:Multivariate Analysis; D009853:Omeprazole / Q000008:administration & dosage; D010406:Penicillins / Q000008:administration & dosage; D012737:Sex Factors; D012907:Smoking; D013752:Tetracycline / Q000008:administration & dosage; D013997:Time Factors; D014945:Wound Healing
D000863:Antacids; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D010406:Penicillins; D008795:Metronidazole; D000658:Amoxicillin; D013752:Tetracycline; D009853:Omeprazole; D001729:Bismuth
De qué factores depende la cicatrización ulcerosa duodenal cuando empleamos un tratamiento erradicador de Helicobacter pylori?